Sign In
Buy CODX
$1.44
-0.120 (-7.69%)
At Close: Jul 31, 2026
Co-Diagnostics Announces Second Quarter 2026 Earnings Release Date and Webcast
09:00am, Thursday, 30'th Jul 2026
SALT LAKE CITY, July 30, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of m
Co-Diagnostics Joint Venture CoSara Provides Ebola Test Kits for Analytical Studies
08:00am, Tuesday, 28'th Jul 2026
Company also completes proof of concept for the first blood-borne test for Ebola on Co-Dx PCR Pro ® instrument SALT LAKE CITY, July 28, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-
Co-Diagnostics Joint Venture CoSara Initiates Clinical Studies in India for Tuberculosis Test on PCR Platform
09:00am, Wednesday, 22'nd Jul 2026
PCR Pro Instruments and MTB Test Kits Now Deployed to Select Labs Across India SALT LAKE CITY, July 22, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecula
Co-Diagnostics Appoints Wes Lindsey, PhD, MBA as Chief Scientific Officer
09:00am, Thursday, 16'th Jul 2026
SALT LAKE CITY, July 16, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of m
Co-Diagnostics Invited to Participate in NPOC Tuberculosis Diagnostics Workshop in Bangkok, Thailand
09:00am, Wednesday, 08'th Jul 2026
Invited by the Stop TB Partnership and the Global Fund to participate as a manufacturer partner Workshop brings together national TB programs, researchers, donors, and technical agencies from 21 coun
Co-Diagnostics Completes Clinical and Analytical Studies in Preparation for FDA 510(k) Submission of Upper Respiratory Point-of-Care Test
09:00am, Wednesday, 01'st Jul 2026
More than 1,400 patients enrolled across 9 clinical sites; analytical performance testing included 27 individual studies and over 10,000 PCR test cup runs Analytical data to support concurrent 510(k)
Co-Diagnostics Vector Smart® Division Expands Footprint to 21 States
09:00am, Thursday, 25'th Jun 2026
Expansion coincides with Co-Dx webinar for prospective mosquito abatement district customers in honor of National Mosquito Control Awareness Week SALT LAKE CITY, June 25, 2026 /PRNewswire/ -- Co-Diag
Co-Diagnostics Advances Latin American Commercialization Strategy for Co-Dx™ PCR Pro® with Mexico Distributor Agreement
09:00am, Thursday, 11'th Jun 2026
Longstanding distribution partner to support future deployment of Co-Dx™ PCR Pro ® and expanding menu of molecular diagnostics products across a key Latin American market SALT LAKE CITY, June 11, 2
Co-Diagnostics and CoSara Advance Ebola PCR Test Development and Co-Dx™ PCR Point-of-Care Platform Capabilities
09:00am, Tuesday, 02'nd Jun 2026
Dual-assay strategy designed to support outbreak response and surveillance efforts in affected regions Potential blood-based Ebola assay would represent an important expansion of Co-Dx™ PCR point-of
Is Co-Diagnostics National Security's Next Diagnostic Pick?
11:03am, Thursday, 28'th May 2026
A structural shift is underway in the biodefense landscape. The declaration of a Public Health Emergency of International Concern (PHEIC) by the World Health Organization on May 17, 2026, for the Bund
Co-Diagnostics Advances Ebola PCR Assay Development Strategy with Joint Venture CoSara
09:00am, Tuesday, 26'th May 2026
Joint development strategy has been developed to address international deployment requirements if current outbreak continues or expands globally SALT LAKE CITY, May 26, 2026 /PRNewswire/ -- Co-Diagnos
Co-Diagnostics Announces $3.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules
10:54pm, Tuesday, 19'th May 2026
SALT LAKE CITY, May 19, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx", or the "Company"), a molecular diagnostics company with a unique, patented platform for the development of m
Co-Diagnostics Develops Ebola Assay Strategy Following Recent Global Outbreak Alert
09:00am, Tuesday, 19'th May 2026
Recent pathogens illustrate need for improved situational awareness capabilities, such as those provided by the Co-Dx PCR point-of-care platform Follows outbreak of Ebola and WHO emergency declaration
Co-Diagnostics, Inc. (CODX) Q1 2026 Earnings Call Transcript
07:10pm, Thursday, 14'th May 2026
Co-Diagnostics, Inc. (CODX) Q1 2026 Earnings Call Transcript
Co-Diagnostics Reports First Quarter 2026 Financial Results
04:01pm, Thursday, 14'th May 2026
Advancing Global Commercialization Through CoSara Regulatory Progress and Regional Expansion Executing Clinical Strategy with Upper Respiratory Submission Preparation and TB Study Initiation Expanding
